PCM
XERS icon

Penn Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Penn Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$491K Sell
62,021
-6,875
-10% -$43.9K 0.03% 166
2026
Q1 		$400K Buy
68,896
+20,832
+43% +$138K 0.03% 161
2025
Q4 		$377K Buy
+48,064
New +$378K 0.03% 157

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Penn Capital Management's XERS Position: Q2 2026 in Review

Penn Capital Management reduced its Xeris Biopharma Holdings (XERS) stake by 10% in Q2 2026, selling an estimated $43.9K and leaving 62,021 shares worth $491K. The position accounts for 0.03% of the portfolio, ranked #166.

Penn Capital Management first reported a position in XERS in Q4 2025 and has held it in 3 quarters since. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Penn Capital Management held 62,021 shares of Xeris Biopharma Holdings worth $491K as of Q2 2026.
  • Penn Capital Management sold 6,875 Xeris Biopharma Holdings shares in Q2 2026, an estimated $43.9K.
  • Xeris Biopharma Holdings made up 0.03% of Penn Capital Management's portfolio in Q2 2026, its #166 holding.
  • Penn Capital Management first reported a position in Xeris Biopharma Holdings in Q4 2025 and has held it in 3 quarters since.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Penn Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.